Phase 1 Interstitial Lung Disease Clinical Trials
7 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
Feasibility of Semaglutide in Advanced Lung Disease
ObesityChronic Obstructive Pulmonary DiseaseInterstitial Lung Disease+2 more
University of Pennsylvania8 enrolled1 locationNCT05746039
Recruiting
Phase 1
A Study of the Pharmacokinetics and Safety of Single-dose Inhaled RJ026 in Healthy Volunteers and Patients With Interstitial Lung Disease
Healthy VolunteersInterstitial Lung Disease (ILD)
Ruijin Hospital84 enrolled1 locationNCT06992661
Recruiting
Phase 1
Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy Trial
Anti-MDA5 Positive Dermatomyositis-Associated RP-ILDRapidly Progressive Interstitial Lung Disease
Li Shiyue10 enrolled1 locationNCT06919380
Recruiting
Phase 1
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
AsthmaCOPDCystic Fibrosis+4 more
Mario Castro, MD, MPH260 enrolled1 locationNCT04624490
Recruiting
Phase 1Phase 2
ADSCs Therapy in Patients With CTD-ILD
Interstitial Lung DiseaseConnective Tissue Diseases
China Medical University Hospital16 enrolled1 locationNCT06574581
Completed
Phase 1
A Phase 1 Study of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow® Nebulizer System in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis or Progressive Fibrosing Interstitial Lung Disease
Progressive, Fibrosing Interstitial Lung DiseasesIdiopathic Pulmonary Fibrosis
Avalyn Pharma Pty Ltd38 enrolled1 locationACTRN12620001141932
Completed
Phase 1
Evaluation of the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Intravenous ATYR1923 in Healthy Volunteers.
Interstitial Lung Disease
INCResearch Australia Pty Ltd36 enrolled1 locationACTRN12617001446358